I-MAB - American Depositary Shares (IMAB)
IMAB moved a median of 0.00% 30 minutes after news, and -0.01% by the close. How IMAB actually reacts to news — the realized, point-in-time move the market made, measured across 180 labeled events over the last three years with zero look-ahead.
IMAB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 163 |
| 30-min | 0.00% | 50% | 163 |
| 60-min | +0.03% | 51% | 163 |
| to close | -0.01% | 44% | 163 |
| Middle 50% of IMAB reactions | -2.69% to +2.28% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 180 |
Half of all I-MAB - American Depositary Shares news events land between -2.69% and +2.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when IMAB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMAB's baseline. Nothing else.
Recent IMAB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K NovaBridge Biosciences For: Oct 31 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Form 6-K NovaBridge Biosciences For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders | Press release | PR Newswire | — | — | |
| Form 6-K NovaBridge Biosciences For: Oct 29 | SEC filing · Form 6-K | SEC EDGAR | — | — | |
| I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform | Press release | PR Newswire | -0.64% | -0.86% | |
| Form 6-K I-Mab For: Oct 28 | SEC filing · Form 6-K | SEC EDGAR | -3.18% | -1.49% | |
| Form 6-K I-Mab For: Oct 24 | SEC filing · Form 6-K | SEC EDGAR | +0.45% | -4.31% | |
| Form 6-K/A I-Mab For: Oct 24 | SEC filing · Form 6-K | SEC EDGAR | -4.54% | -4.09% | |
| Form 6-K I-Mab For: Oct 23 | SEC filing · Form 6-K | SEC EDGAR | -4.54% | -4.09% | |
| Form 6-K I-Mab For: Oct 22 | SEC filing · Form 6-K | SEC EDGAR | +0.21% | +1.69% | |
| I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 | Press release | GlobeNewswire | +0.63% | +1.90% | |
| I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | Press release | PR Newswire | -4.27% | -8.41% | |
| Form 6-K I-Mab For: Oct 16 | SEC filing · Form 6-K | SEC EDGAR | -4.27% | -8.41% | |
| I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences | Press release | GlobeNewswire | -4.27% | -8.41% | |
| I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference | Press release | GlobeNewswire | -0.26% | +8.80% | |
| Form 6-K I-Mab For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -3.16% | -1.81% | |
| Form 6-K I-Mab For: Sep 24 | SEC filing · Form 6-K | SEC EDGAR | -1.64% | -3.56% | |
| Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight | Press release | PR Newswire | -1.33% | +2.76% | |
| Form S-8 I-Mab | SEC filing · Form S-8 | SEC EDGAR | -2.05% | +4.87% | |
| Form 6-K I-Mab For: Sep 03 | SEC filing · Form 6-K | SEC EDGAR | -1.58% | -3.61% | |
| I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments | Press release | GlobeNewswire | -1.58% | -3.61% | |
| Everest Medicines Announces Interim Results for First Half of 2025 | Press release | PR Newswire | -6.26% | -3.48% | |
| Form 6-K I-Mab For: Aug 22 | SEC filing · Form 6-K | SEC EDGAR | +0.19% | -7.31% | |
| I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee | Press release | GlobeNewswire | +0.19% | -7.31% | |
| I-Mab to Participate in September Investor Conferences | Press release | GlobeNewswire | +0.00% | +7.53% | |
| Form 6-K I-Mab For: Aug 20 | SEC filing · Form 6-K | SEC EDGAR | +5.61% | +8.92% | |
| I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +5.61% | +8.92% | |
| Form 6-K I-Mab For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | +2.58% | +11.46% | |
| I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers | Press release | GlobeNewswire | +2.58% | +11.46% | |
| Form 6-K I-Mab For: Aug 04 | SEC filing · Form 6-K | SEC EDGAR | -5.84% | -4.87% | |
| Everest Medicines Expands Strategic Investment in I-MAB | Press release | PR Newswire | +13.72% | +15.93% | |
| Form 6-K I-Mab For: Aug 01 | SEC filing · Form 6-K | SEC EDGAR | +13.72% | +15.93% | |
| I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares | Press release | GlobeNewswire | +13.72% | +15.93% | |
| Form 6-K I-Mab For: Jul 17 | SEC filing · Form 6-K | SEC EDGAR | +1.39% | +0.00% | |
| I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health | Press release | GlobeNewswire | +1.39% | +0.00% | |
| I-Mab to Present at the BTIG Virtual Biotechnology Conference | Press release | GlobeNewswire | +1.13% | +2.39% | |
| Form 6-K I-Mab For: Jul 11 | SEC filing · Form 6-K | SEC EDGAR | +1.13% | +2.39% | |
| Form 6-K/A I-Mab For: Jul 11 | SEC filing · Form 6-K | SEC EDGAR | +1.13% | +2.39% | |
| Form 6-K I-Mab For: Jul 02 | SEC filing · Form 6-K | SEC EDGAR | -5.65% | -6.29% | |
| I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 | Press release | GlobeNewswire | -1.75% | +0.00% | |
| I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research | Press release | GlobeNewswire | +1.23% | -3.70% | |
| Form 6-K I-Mab For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | -8.81% | -31.52% | |
| I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025 | Press release | GlobeNewswire | -8.81% | -31.52% | |
| I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025 | Press release | GlobeNewswire | +1.45% | -3.32% | |
| Form 6-K I-Mab For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | +1.89% | +8.40% | |
| I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +1.89% | +8.40% | |
| I-Mab to Participate in the H.C. Wainwright “HCW@Home” Series | Press release | GlobeNewswire | +1.17% | +46.09% | |
| Form 6-K I-Mab For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | -2.98% | -4.48% | |
| Form 6-K I-Mab For: May 30 | SEC filing · Form 6-K | SEC EDGAR | -6.24% | -9.03% | |
| I-Mab to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.35% | -0.70% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMAB section they belong to.
Where else IMAB is measured.
IMAB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is I-MAB - American Depositary Shares's median reaction calculated?
Every labeled IMAB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 180 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of IMAB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMAB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.